XBiotech, Inc: XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus

Report Documents 514G3's Ability to Protect Mice Against Deadly S. aureus
Bacteremia Infections 

AUSTIN, Texas, 2018-01-25 14:00 CET (GLOBE NEWSWIRE) --
XBiotech Inc. (NASDAQ:XBIT) announced today the publication of "A Natural Human
Monoclonal Antibody Targeting Staphylococcus Protein A Protects Against
Staphylococcus aureus (S. aureus) Bacteremia." in the journal PLOS ONE. The
article reports on research involving the Company's therapeutic monoclonal
antibody, 514G3, and its ability to neutralize a key immune evasion mechanism
of S. aureus involved in the establishment of serious or even deadly
infections. The 514G3 antibody was a naturally occurring antibody derived from
a healthy individual with highly targeted immunity against S. aureus capable of
neutralizing all strains of the bacteria, including a drug-resistant or
so-called MRSA form. 

"Continued emergence of multi drug resistant strains of S. aureus along with
increased aging and immunocompromised populations, contribute to a need for new
solutions to this deadly infection," commented Dr. Sushma Shivaswamy, Ph.D.,
XBiotech's Chief Scientific Officer. She further stated, "The present study
confirms the mechanism of action of 514G3, and its ability to neutralize and
kill the bacteria in a strain-independent manner." 

The Company has previously announced top-line results from a Phase I/II
clinical study, which reported a reduction in adverse events and shorter
hospitalization associated with the 514G3 therapy, even with 514G3-treated
patients tending to be sicker than those receiving placebo. The U.S. FDA has
recognized the potential of this treatment, designating this as a Fast Track
development program. 

About True Human Therapeutic Antibodies
XBiotech's True Human antibodies are derived without modification from
individuals who possess natural immunity to certain diseases. With discovery
and clinical programs across multiple disease areas, XBiotech's True Human
antibodies have the potential to harness the body's natural immunity to fight
disease with increased safety, efficacy and tolerability. 

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of therapeutic
antibodies based on its True Human proprietary technology. XBiotech currently
is advancing a robust pipeline of antibody therapies to redefine the standards
of care in oncology, inflammatory conditions and infectious diseases.
Headquartered in Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more rapidly,
cost-effectively and flexibly produce new therapies urgently needed by patients
worldwide. For more information, visit www.xbiotech.com. 

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations
regarding management's beliefs and expectations that involve substantial risks
and uncertainties. In some cases, you can identify forward-looking statements
by terminology such as "may," "will," "should," "would," "could," "expects,"
"plans," "contemplate," "anticipates," "believes," "estimates," "predicts,"
"projects," "intend" or "continue" or the negative of such terms or other
comparable terminology, although not all forward-looking statements contain
these identifying words. Forward-looking statements are subject to inherent
risks and uncertainties in predicting future results and conditions that could
cause the actual results to differ materially from those projected in these
forward-looking statements. These risks and uncertainties are subject to the
disclosures set forth in the "Risk Factors" section of certain of our SEC
filings. Forward-looking statements are not guarantees of future performance,
and our actual results of operations, financial condition and liquidity, and
the development of the industry in which we operate, may differ materially from
the forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak only as of
the date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information, future
events or otherwise, after the date of this press release. 

         Contact
         Ashley Otero
         [e-mail]
         512-386-2930